X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs ASTRAZENECA PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES ASTRAZENECA PHARMA PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 10.4 161.7 6.4% View Chart
P/BV x 1.8 25.1 7.1% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 PIRAMAL ENTERPRISES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
ASTRAZENECA PHARMA
Mar-14
PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,0831,285 239.9%   
Low Rs1,902634 300.0%   
Sales per share (Unadj.) Rs589.7189.6 311.1%  
Earnings per share (Unadj.) Rs284.0-0.2 -139,505.9%  
Cash flow per share (Unadj.) Rs310.53.8 8,077.0%  
Dividends per share (Unadj.) Rs25.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs1,467.068.6 2,137.2%  
Shares outstanding (eoy) m180.2725.00 721.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.25.1 83.5%   
Avg P/E ratio x8.8-4,712.7 -0.2%  
P/CF ratio (eoy) x8.0249.6 3.2%  
Price / Book Value ratio x1.714.0 12.2%  
Dividend payout %8.80-   
Avg Mkt Cap Rs m449,33223,988 1,873.2%   
No. of employees `0006.81.6 438.9%   
Total wages/salary Rs m19,8811,605 1,239.0%   
Avg. sales/employee Rs Th15,535.63,040.2 511.0%   
Avg. wages/employee Rs Th2,905.41,029.2 282.3%   
Avg. net profit/employee Rs Th7,482.5-3.3 -229,179.4%   
INCOME DATA
Net Sales Rs m106,3104,740 2,243.0%  
Other income Rs m2,59592 2,817.9%   
Total revenues Rs m108,9064,832 2,253.9%   
Gross profit Rs m51,599-130 -39,752.5%  
Depreciation Rs m4,773101 4,716.7%   
Interest Rs m29,7830-   
Profit before tax Rs m19,638-139 -14,138.0%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m-28,7645 -565,112.0%   
Profit after tax Rs m51,203-5 -1,005,948.9%  
Gross profit margin %48.5-2.7 -1,772.3%  
Effective tax rate %-146.5-3.7 3,997.1%   
Net profit margin %48.2-0.1 -44,849.0%  
BALANCE SHEET DATA
Current assets Rs m118,1542,726 4,333.7%   
Current liabilities Rs m462,2602,435 18,984.0%   
Net working cap to sales %-323.76.1 -5,264.8%  
Current ratio x0.31.1 22.8%  
Inventory Days Days2774 36.0%  
Debtors Days Days4741 114.2%  
Net fixed assets Rs m113,7271,035 10,984.9%   
Share capital Rs m36150 721.0%   
"Free" reserves Rs m264,093942 28,023.5%   
Net worth Rs m264,4541,716 15,411.1%   
Long term debt Rs m242,2060-   
Total assets Rs m726,8344,156 17,488.8%  
Interest coverage x1.7NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.11.1 12.8%   
Return on assets %11.1-0.1 -9,097.7%  
Return on equity %19.4-0.3 -6,527.4%  
Return on capital %10.30-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m15,110375 4,033.6%   
Fx outflow Rs m4,298470 914.1%   
Net fx Rs m10,813-96 -11,316.1%   
CASH FLOW
From Operations Rs m-159,666-8 1,971,184.0%  
From Investments Rs m-17,677-146 12,132.7%  
From Financial Activity Rs m186,503862 21,631.0%  
Net Cashflow Rs m9,364709 1,321.7%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 0.3 1,333.3%  
FIIs % 26.6 15.7 169.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 9.1 181.3%  
Shareholders   93,274 12,856 725.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

The BSE HEALTHCARE Index Down 2% ; VIVIMED LABS LTD Among Top Losers (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

The BSE HEALTHCARE Index Down at 16,043 (down 2.3%). Among the top losers in the BSE HEALTHCARE Index today are VIVIMED LABS LTD, VIMTA LABS and RPG LIFE SCIENCES. Meanwhile, the BSE Sensex has plunged 0.7% to 37,489.

IPCA LABS Plunges by 6%; BSE HEALTHCARE Index Down 1.8% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

IPCA LABS share price has plunged by 6% and its current market price is Rs 755. The BSE HEALTHCARE is down by 1.8%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 3.8%) and ERIS LIFESCIENCES LIMITED (up 3.6%). The top losers are IPCA LABS (down 5.9%) and PIRAMAL ENTERPRISES (down 5.3%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 21, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS